Wells Fargo lowers BioNTech stock price target to $150 on model updates

Published 05/08/2025, 10:56
Wells Fargo lowers BioNTech stock price target to $150 on model updates

Investing.com - Wells Fargo (NYSE:WFC) lowered its price target on BioNTech (NASDAQ:BNTX) to $150.00 from $170.00 on Tuesday, while maintaining an Overweight rating on the stock. According to InvestingPro data, the company maintains a strong financial position with a healthy balance sheet, holding more cash than debt.

The price target reduction reflects model updates incorporating BioNTech’s collaboration with Bristol Myers (NYSE:BMY) Squibb, according to the research firm.

BioNTech reported second-quarter revenues ahead of expectations, benefiting from COVID-related government revenues and a one-time payment from Pfizer (NYSE:PFE). The company’s R&D expenses were lower due to trial reprioritization, and management reaffirmed both topline and R&D guidance for 2025.

Wells Fargo noted several upcoming oncology updates expected this year, including BNT327 dose optimization data that will determine Phase 3 trial starts and the first adjuvant setting readout for the company’s personalized cancer vaccine.

Management anticipates declining COVID vaccination rates but expects to maintain similar market share above 50% and pricing comparable to 2024 levels, while emphasizing the strategic importance of its vaccine business as the company focuses more deeply on oncology. For detailed analysis and additional insights, including 8 more exclusive ProTips, check out the comprehensive research report available on InvestingPro.

In other recent news, BioNTech reported its second-quarter 2025 revenue, which doubled year-over-year to €260.8 million, surpassing analyst estimates of €137.9 million. Despite this impressive revenue growth, the company posted a net loss of €386.6 million, or -€1.60 per share, slightly worse than the expected -€1.41 per share. TD Cowen raised its price target for BioNTech from $110 to $120, citing the strong Comirnaty sales of €153 million, which exceeded both consensus estimates and the firm’s own projections. Clear Street also adjusted its price target for BioNTech, increasing it from $181 to $185, while maintaining a Buy rating. This adjustment followed BioNTech’s reported revenues of €261 million, which outperformed consensus estimates of €151 million. Additionally, a recent deal with Bristol Myers has bolstered BioNTech’s outlook. These developments reflect a period of significant activity for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.